48 Results

People

  1. Gounder
    Gounder
  2. Konner
    Konner
  3. Abrey
    Abrey
  4. Chapman
    Chapman
  5. Dickson
    Dickson
  6. Francis
    Francis
  7. Grimm
    Grimm
  8. Lendvai
    Lendvai
  9. Marr
    Marr
  10. Momtaz
    Momtaz

Groups

  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (23)
  3. Hematologic Malignancies, Division of (9)
  4. Center for Hematologic Malignancies (8)
  5. Surgery (8)
  6. Gynecologic Medicine Service (5)
  7. Gynecology Disease Management Team (5)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  9. GDMT, Medicine (4)
  10. Gastrointestinal Oncology Service (4)
  1. "blurred vision"
Formats
  1. Journal Article (41)
  2. Review (4)
  3. Research Letter (3)
Groups
  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (23)
  3. Hematologic Malignancies, Division of (9)
  4. Center for Hematologic Malignancies (8)
  5. Surgery (8)
  6. Gynecologic Medicine Service (5)

More Groups

People
  1. Jasmine Francis (3)
  2. Jason Konner (3)
  3. Mrinal Gounder (3)
  4. Paul Chapman (3)
  5. Anas Younes (2)
  6. Brian Marr (2)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (2)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (6)

More Years

Publications
  1. Clinical Cancer Research (4)
  2. Journal of Clinical Oncology (3)
  3. Lancet Oncology (3)
  4. American Journal of Ophthalmology Case Reports (2)
  5. Cancer (2)
  6. Gynecologic Oncology (2)

More Publications

Publishers
  1. Elsevier Inc. (9)
  2. Nature Publishing Group (5)
  3. American Association for Cancer Research (4)
  4. American Society of Clinical Oncology (4)
  5. Elsevier Science, Inc. (4)
  6. Wiley Blackwell (4)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
    Research Letter

    Lee, H. C.; Raje, N. S.; Landgren, O.; Upreti, V. V.; Wang, J.; Avilion, A. A.; Hu, X.; Rasmussen, E.; Ngarmchamnanrith, G.; Fujii, H.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • The METeoric rise of MET in lung cancer
    Review

    Friedlaender, A.; Drilon, A.; Banna, G. L.; Peters, S.; Addeo, A.
    Cancer (2020)

    Fulltext@MSK | Save
  • Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment
    Journal Article

    van Landingham, S. W.; Puccetti, D.; Potter, H.; Gamm, D.; Diamond, E. L.; Lucarelli, M. J.
    American Journal of Ophthalmology Case Reports (2020)

    Fulltext@MSK | Save
  • Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma
    Review

    Peterson, T. J.; Orozco, J.; Buege, M.
    Annals of Pharmacotherapy (2020)

    Fulltext@MSK | Save
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia
    Journal Article

    Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials
    Research Letter

    Atkinson, T. M.; Dueck, A. C.; Satele, D. V.; Thanarajasingam, G.; Lafky, J. M.; Sloan, J. A.; Basch, E.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study
    Journal Article

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N.; Lendvai, N.; Sborov, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations
    Journal Article

    Hyman, D. M.; Tran, B.; Paz-Ares, L.; Machiels, J. P.; Schellens, J. H.; Bedard, P. L.; Campone, M.; Cassier, P. A.; Sarantopoulos, J.; Vaishampayan, U.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
    Research Letter

    Mascarenhas, J.; Kosiorek, H.; Prchal, J.; Yacoub, A.; Berenzon, D.; Baer, M. R.; Ritchie, E.; Silver, R. T.; Kessler, C.; Winton, E.; more...
    Leukemia (2019)

    Fulltext@MSK | Save